NCT00502060View on ClinicalTrials.gov

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Advanced Tumor
Interventions
DRUG

AZD2171

DRUG

ZD1839

Trial Locations (3)

Unknown

Research Site, Amsterdam

Research Site, Nijmegen

Research Site, Utrecht

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY